logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

'They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan

Stringer B, Lowton K, Tillashaikhov M, Parpieva N, Ulmasova D,  et al.
2016-08-01 • International Journal of Tuberculosis and Lung Disease
2016-08-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The joint Médecins Sans Frontières/Ministry of Health Multidrug-Resistant Tuberculosis (MDR-TB) Programme, Karakalpakstan, Uzbekistan.

OBJECTIVE
Uzbekistan has h...
Journal Article
|
Research

Where there is hope: A qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

Horter SCB, Stringer B, Greig J, Amangeldiev A, Tillashaikhov M,  et al.
2016-07-28 • BMC Infectious Diseases
2016-07-28 • BMC Infectious Diseases
BACKGROUND
Treatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Mi...
Journal Article
|
Research

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

du Cros PAK, Khamraev AK, Tigay Z, Abdrasuliev T, Greig J,  et al.
2021-02-08 • ERJ open research
2021-02-08 • ERJ open research
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....